Pharmacological activation of PPARγ ameliorates insulin resistance in diabetes, and has been reported to decrease liver damage in NAFLD by restoring adipose tissue insulin sensitivity, thus decreasing FFAs flux to the liver [30,31]. Here, PPARG is linked to diabetes mellitus.